Lexaria Bioscience Corp. cash flow to debt ratio of -9.56K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Lexaria Bioscience Corp.'s free cash flow has decreased 109.42% from $-5.00M last year to $-10.48M, signaling decreasing performance

Lexaria Bioscience Corp.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

Lexaria Bioscience Corp.'s debt has increased relative to shareholder equity from 0.02 last year to 0.02 today, signaling weakened financials

Lexaria Bioscience Corp. has a net cash position, so leverage is healthy.

Lexaria Bioscience Corp. earns at least as much interest as it pays. Interest obligations are fully covered.

Lexaria Bioscience Corp.'s profit margin has decreased (219.29%) in the last year from -1.25K% to -3.99K%, signaling decreasing performance

Lexaria Bioscience Corp.'s short-term assets of $3.47M exceed its short-term liabilities of $1.49M

Lexaria Bioscience Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Lexaria Bioscience Corp.'s return on equity of -160.72%, is lower than 15.00%, indicating bad performance

Lexaria Bioscience Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Lexaria Bioscience Corp. had positive net income in only 0 out of 5 years, indicating unstable earnings

Lexaria Bioscience Corp. has negative free cash flow, indicating the company is burning cash rather than generating it

Lexaria Bioscience Corp. has negative free cash flow, indicating cash burn

Lexaria Bioscience Corp.'s yearly earnings has decreased 105.37% since last year from $-5.80M to $-11.90M, signaling decreasing performance

Lexaria Bioscience Corp.'s yearly revenue has increased 52.05% since last year from $464.28K to $705.92K, signaling increasing performance

ROIC -173.96% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Lexaria Bioscience Corp.'s 3-year revenue CAGR of 40.34% is positive, indicating growing revenue over the past 3 years

Lexaria Bioscience Corp. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Lexaria Bioscience Corp. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Lexaria Bioscience Corp. has insufficient data to evaluate this check.

Lexaria Bioscience Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lexaria Bioscience Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Lexaria Bioscience Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Lexaria Bioscience Corp. has insufficient data to evaluate this check.

Lexaria Bioscience Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lexaria Bioscience Corp. has a price-to-book ratio of 2.09x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Lexaria Bioscience Corp. has a price-to-sales ratio of 46.80x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue